Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71, 209–249. https://doi.org/10.3322/caac.21660 (2021).
Liu, T., Song, S., Wang, X. & Hao, J. Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer. Eur. J. Med. Chem. 210, 112954. https://doi.org/10.1016/j.ejmech.2020.112954 (2021).
Roberto, M. et al. CDK4/6 inhibitor treatments in patients with hormone receptor positive, Her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives. Cancers (Basel) https://doi.org/10.3390/cancers13020332 (2021).
Collin, L. J. et al. Early discontinuation of endocrine therapy and recurrence of breast cancer among premenopausal women. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-20-3974 (2020).
Ouyang, P., Michos, E. D. & Karas, R. H. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J. Am. Coll. Cardiol. 47, 1741–1753. https://doi.org/10.1016/j.jacc.2005.10.076 (2006).
Akyol, M. et al. The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy. Cancer Biomark 18, 441–449. https://doi.org/10.3233/CBM-161507 (2017).
He, T. et al. Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis. Med. (Baltim.) 99, e18550. https://doi.org/10.1097/MD.0000000000018550 (2020).
Afifi, A. M. et al. Causes of death after breast cancer diagnosis: A US population-based analysis. Cancer 126, 1559–1567. https://doi.org/10.1002/cncr.32648 (2019).
Anagnostis, P. et al. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas 135, 82–88. https://doi.org/10.1016/j.maturitas.2020.03.007 (2020).
Franchi, M., Tritto, R., Tarantini, L., Navazio, A. & Corrao, G. Adjuvant hormonotherapy and cardiovascular risk in post-menopausal women with breast cancer: A large population-based cohort study. Cancers (Basel) https://doi.org/10.3390/cancers13092254 (2021).
Borgquist, S. et al. Cholesterol, cholesterol-lowering medication use, and breast cancer outcome in the BIG 1–98 study. J. Clin. Oncol. 35, 1179–1188. https://doi.org/10.1200/JCO.2016.70.3116 (2017).
Nelson, E. R. The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer. Mol. Cell Endocrinol. 466, 73–80. https://doi.org/10.1016/j.mce.2017.09.021 (2018).
Lintermans, A. & Neven, P. Safety of aromatase inhibitor therapy in breast cancer. Expert Opin. Drug Saf. 14, 1201–1211. https://doi.org/10.1517/14740338.2015.1053458 (2015).
Li, X. et al. Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy. Lipids Health Dis. 17, 91. https://doi.org/10.1186/s12944-018-0745-1 (2018).
Montemurro, F., Perrone, F. & Geuna, E. Adjuvant ovarian suppression in premenopausal breast cancer. N. Engl. J. Med. 372, 1672–1673. https://doi.org/10.1056/NEJMc1502618 (2015).
Gaibar, M. et al. Tamoxifen therapy in breast cancer: Do apolipoprotein E genotype and menopausal state affect plasma lipid changes induced by the drug?. Int. J. Biol. Mark. 28, e371-376. https://doi.org/10.5301/jbm.5000037 (2013).
Dnistrian, A. M., Schwartz, M. K., Greenberg, E. J., Smith, C. A. & Schwartz, D. C. Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy. Clin. Chim. Acta 223, 43–52. https://doi.org/10.1016/0009-8981(93)90061-8 (1993).
Yang, H. et al. Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: A randomised controlled clinical trial. Br. J. Cancer 109, 582–588. https://doi.org/10.1038/bjc.2013.324 (2013).
Bellet, M. et al. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy. J. Clin. Oncol. 34, 1584–1593. https://doi.org/10.1200/JCO.2015.61.2259 (2016).
Ramchand, S. K., Lim, E. & Grossmann, M. Adjuvant endocrine therapy in women with oestrogen-receptor-positive breast cancer: How should the skeletal and vascular side effects be assessed and managed?. Clin. Endocrinol. (Oxf.) 85, 689–693. https://doi.org/10.1111/cen.13172 (2016).
Boccardo, F. et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann. Oncol. 17(Suppl 7), vii10-14. https://doi.org/10.1093/annonc/mdl941 (2006).
Williams, N. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9, 45–53 (2008).
Goss, P. E. et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349, 1793–1802. https://doi.org/10.1056/NEJMoa032312 (2003).
Kawase, T. et al. Association between vitamin D and calcium intake and breast cancer risk according to menopausal status and receptor status in Japan. Cancer Sci. 101, 1234–1240. https://doi.org/10.1111/j.1349-7006.2010.01496.x (2010).
Pagani, O. et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N. Engl. J. Med. 371, 107–118. https://doi.org/10.1056/NEJMoa1404037 (2014).
Tian, W., Wu, M. & Deng, Y. Comparison of changes in the lipid profiles of eastern chinese postmenopausal women with early-stage breast cancer treated with different aromatase inhibitors: A retrospective study. Clin. Pharmacol. Drug Dev. 7, 837–843. https://doi.org/10.1002/cpdd.420 (2018).
Zhao, X. et al. Comparative study on individual aromatase inhibitors on cardiovascular safety profile: A network meta-analysis. Oncol. Targets Ther. 8, 2721–2730. https://doi.org/10.2147/OTT.S88179 (2015).
Ntukidem, N. I. et al. Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin. Pharmacol. Ther. 83, 702–710. https://doi.org/10.1038/sj.clpt.6100343 (2008).
McCloskey, E. V. et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur. J. Cancer 43, 2523–2531. https://doi.org/10.1016/j.ejca.2007.08.029 (2007).
Smith, I. et al. Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: Final results of the randomized phase III femara versus anastrozole clinical evaluation (FACE) trial. J. Clin. Oncol. 35, 1041–1048. https://doi.org/10.1200/JCO.2016.69.2871 (2017).
Wang, X. et al. Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: A prospective cohort study. Ther. Adv. Med. Oncol. 12, 1758835920925991. https://doi.org/10.1177/1758835920925991 (2020).
Santa-Maria, C. A. et al. Association of variants in candidate genes with lipid profiles in women with early breast cancer on adjuvant aromatase inhibitor therapy. Clin. Cancer Res. 22, 1395–1402. https://doi.org/10.1158/1078-0432.CCR-15-1213 (2016).
Yeo, W. et al. Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy. BMC Womens Health 17, 55. https://doi.org/10.1186/s12905-017-0409-8 (2017).